Contributions
Abstract: P1291
Type: Poster
Abstract Category: Therapy - disease modifying - Others
Objective: NeuromyelitisOptica (NMO)/ NeuromyelitisOptica Spectrum (NMOSD) encompass astrocytopatic and immune-mediated chronicinflammatory disease of the central nervous system(CNS). Unlike patients with MS, NMOSD attacks are more severe with predominance in spinal cord and optic nerves. In this study we evaluated our NMO/NMOSDpatients diagnosed according to the international criteria 2015.
Material and method: Demographic,clinical,laboratory and MRI features in 46 NMOSD patients who have been followed up in our center between 2002-2016 were documented. Age, gender, comorbidities, AQP4 antibodies,autoimmune and serologic markers, initial symptoms, number of attacks, long term treatment responses, MRI findings were analyzedin relation to their prognosis and outcomes.
Results: 46 patientswere evaluated(40 women-6 men) mean age at onset 36.8. Among them 26 were AQP4-Antibody positive.
11 patients have other autoimmune diseases such as Sjögren syndrome(n=7), Hashimoto thyroiditis(n=2) myasthenia gravis(n=1) idiopathic thrombocytopenic purpura(n=1) autoimmune hepatitis (n=1).7 of this 11 patients were AQP4-Antibody positive.
16 patients had antibodies associated with connective tissue disorders such as ANA ENA, antiphospholipid antibodies, ANCA. 4 patients who have AQP4-Ab negative NMO had antibodies to myelin oligodendrocyte glycoprotein(MOG).
Clinically, 34 NMOSD patients startedmonosymptomatic( ON), others hadmultiple symptomatology. Theirmean EDSS score was 3.5 and their mean number of attacks were3.4.
MRI findings were classified in four categories; Supratentorial(n=15 ), Optic nerve(n=11), Brainstem(n=16), Longitudinally extended tranvers myelitis(LETM)(n=40 ).
I.V. methylprednisolone(n=43 ), IVIg(n=3) and therapeutic plasma exchange(n=16)were selected for treatment of acute episodes. Azathioprine(n=25), cyclophosphamide(n=12), oral steroids(n=8), rituximab(n=4), methotrexate(n=1), eculizumab(n=1) were used for long term treatment.
Conclusion: We evaluated and compared NMO and NMOSD patients for their similarities and differences. The prognosis and outcomes were not different between the two groups.
However,in NMOSD patients monosymptomaticonset demonstrated significantly lower EDSSlevels compared to polysymptomaticonset; this difference was reflected on the disease progression index( Diseaseduration / EDSS ).
Disclosure: EzgiYilmaz: nothing to disclose
Abstract: P1291
Type: Poster
Abstract Category: Therapy - disease modifying - Others
Objective: NeuromyelitisOptica (NMO)/ NeuromyelitisOptica Spectrum (NMOSD) encompass astrocytopatic and immune-mediated chronicinflammatory disease of the central nervous system(CNS). Unlike patients with MS, NMOSD attacks are more severe with predominance in spinal cord and optic nerves. In this study we evaluated our NMO/NMOSDpatients diagnosed according to the international criteria 2015.
Material and method: Demographic,clinical,laboratory and MRI features in 46 NMOSD patients who have been followed up in our center between 2002-2016 were documented. Age, gender, comorbidities, AQP4 antibodies,autoimmune and serologic markers, initial symptoms, number of attacks, long term treatment responses, MRI findings were analyzedin relation to their prognosis and outcomes.
Results: 46 patientswere evaluated(40 women-6 men) mean age at onset 36.8. Among them 26 were AQP4-Antibody positive.
11 patients have other autoimmune diseases such as Sjögren syndrome(n=7), Hashimoto thyroiditis(n=2) myasthenia gravis(n=1) idiopathic thrombocytopenic purpura(n=1) autoimmune hepatitis (n=1).7 of this 11 patients were AQP4-Antibody positive.
16 patients had antibodies associated with connective tissue disorders such as ANA ENA, antiphospholipid antibodies, ANCA. 4 patients who have AQP4-Ab negative NMO had antibodies to myelin oligodendrocyte glycoprotein(MOG).
Clinically, 34 NMOSD patients startedmonosymptomatic( ON), others hadmultiple symptomatology. Theirmean EDSS score was 3.5 and their mean number of attacks were3.4.
MRI findings were classified in four categories; Supratentorial(n=15 ), Optic nerve(n=11), Brainstem(n=16), Longitudinally extended tranvers myelitis(LETM)(n=40 ).
I.V. methylprednisolone(n=43 ), IVIg(n=3) and therapeutic plasma exchange(n=16)were selected for treatment of acute episodes. Azathioprine(n=25), cyclophosphamide(n=12), oral steroids(n=8), rituximab(n=4), methotrexate(n=1), eculizumab(n=1) were used for long term treatment.
Conclusion: We evaluated and compared NMO and NMOSD patients for their similarities and differences. The prognosis and outcomes were not different between the two groups.
However,in NMOSD patients monosymptomaticonset demonstrated significantly lower EDSSlevels compared to polysymptomaticonset; this difference was reflected on the disease progression index( Diseaseduration / EDSS ).
Disclosure: EzgiYilmaz: nothing to disclose